This area seeks to develop the science and tools that can help repair or replace damaged or diseased human cells or tissues to restore normal function. It could address a number of currently incurable degenerative conditions and help revolutionise treatment in the 21st century.
Regenerative medicine is an interdisciplinary field that seeks to develop the science and tools that can help repair or replace damaged or diseased human cells or tissues to restore normal function. It holds the promise of revolutionising treatment in the 21st century. It may involve:
- transplanting stem cells, progenitor cells or tissue, stimulating the body’s own repair processes
- using cells as delivery vehicles for therapeutic agents such as genes and cytokines
- using biomaterials to support tissue regeneration.
All regenerative medicine strategies depend upon harnessing, stimulating or guiding endogenous developmental or repair processes. Accordingly, stem cell research plays a central role in regenerative medicine, which also spans the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, biomaterials (scaffolds and matrices), chemical biology and nanotechnology.
Research and development on advanced therapeutics including regenerative medicine is a priority for MRC, and we are committed to supporting research in this area, towards improving human health. Projects will be suitable for a number of different funding mechanisms, depending on their stage along the pathway from basic biomedical research to translation.
We also support a range of strategic investments within the broader MRC regenerative medicine research portfolio. This includes research institutes, cross-council research partnerships and critical research facilities and resources that underpin and enable community ambitions.
Find out about the institutes, units and centres we fund.
The network of Innovation Hubs for Gene Therapies is a £18 million initiative designed to accelerate academic-led development of novel gene therapies throughout the UK. It aims to advance the clinical development of new genetic treatments through the production of GMP (Good Manufacturing Practice) viral vectors, alongside translational support and regulatory advice. The network was set up in 2021 with funding from the Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council (MRC) and the independent research charity LifeArc.